Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on HORIZON DISCOVERY GROUP PLC. We currently have 69 research reports from 5 professional analysts.
|24Mar17 07:00||RNS||Additional Listing|
|23Mar17 11:24||RNS||Holdings in Company|
|20Mar17 10:42||RNS||Holdings in Company|
|14Mar17 07:00||RNS||Agreement for NIPT Reference Standards|
|23Feb17 07:00||RNS||Site Visit|
|20Feb17 13:21||RNS||Holding(s) in Company|
|15Feb17 07:00||RNS||Additional Listing|
Frequency of research reports
Research reports on
HORIZON DISCOVERY GROUP PLC
HORIZON DISCOVERY GROUP PLC
N+1 Singer - Horizon Discovery Group - Agreement in pre-natal diagnostics
14 Mar 17
The extension of an existing Master Services Agreement to include the development of molecular standards for pre-natal testing assays represents an exciting foray into high-volume, liquid biopsy applications of Horizon’s leading gene editing technology. We continue to believe that Horizon’s reference standards are increasingly becoming the industry standard, and reiterate our Buy recommendation with an unchanged target price of 194p.
N+1 Singer - Morning Song 14-03-2017
14 Mar 17
Advanced Medical Solutions (AMS LN) Prelims slightly ahead, still no deals | Brady (BRY LN) Investment will impact profits, but provide a platform for stronger growth | Burford Capital (BUR LN) Strong growth, many opportunities | First Derivatives (FDP LN) Collaboration agreement | Gresham Technologies (GHT LN) A milestone year | Gym Group (GYM LN) In line finals | Horizon Discovery Group (HZD LN) Agreement in pre-natal diagnostics | Kalibrate Technologies (KLBT LN) Near-term challenges, building long-term value | Stadium Group (SDM LN) Strong current trading; Strategic US investment | Zotefoams (ZTF LN) Currency tailwind underpins strong PBT growth; promising HPP progress
15 Feb 17
"Federal Reserve Chairwoman Janet Yellen may be gearing up to raise short-term interest rates at March's FOMC policy meeting after all. While Fund Futures had suggested a June rise was more likely, her optimistic note during yesterday's semi-annual testimony to Congress nevertheless meant that equity traders took the news in their stride while the US$ spike higher. Suggesting that it would be 'unwise' to delay, she painted a largely upbeat picture of the U.S. economy in her first congressional testimony since President Trump took office, noting employment gains in recent months plus higher wage growth, was "a further indication that the job market is tightening". Inflation meanwhile has moved closer to the Fed's 2% objective, while the December personal-consumption expenditures price index moved up 1.6% from a year earlier, a rate last seen in September 2014. Similarly in the UK, yesterday's January CPI figures confirmed the fastest annual rate in 30 months, driven by the Pound's tumble following Brexit, although the figure itself emerged marginally below expectations and led to a minor sell-off of Sterling as rate hike expectations receded somewhat. That said, an increasing school of thought suggests UK inflation may be allowed to rise above the BoE's own 2% CPI target and 'run hot' through most of 2017, assuming it does not breach the 3% level, for fear of Governor Carney otherwise stifling economic momentum during forthcoming Brexit negotiation. The overnight markets accordingly all made further convincing gains, with all principal US markets rising similarly, led by financials and tech stocks as both the S&P500 and NASDAQ chalked-up their sixth consecutive upward moves. Asia went even further, with the Nikkei initially leading the surge as US$:Yen touched a new monthly high, although most other bourse in the region rapidly caught up to close with similar 1% or thereabouts gains, leaving only the Shanghai Composite to end in the negative as fears regarding looming US protectionist measures were resurrected once again. Wednesday will see another large batch of macro releases, with the UK due to detail Average Earnings and Unemployment, while the EU publishes its December Trade Balance and the US delivers its Retail Sales and CPI. No significant earnings or trading updates are anticipated from UK corporates this morning, although some second-liners like Animalcare Group (ANCR.L), NEX Group (NXG.L), QinetiQ Group (QQ..L) and Tracsis (TRCS.L) are scheduled. In the absence of other significant news, London is set to follow the international trend, rising broadly from this morning's opening with the FTSE-100 seen up 20 to 25 points in early trade." - Barry Gibb, Research Analyst
PG: Growth Prospects in Healthcare
26 Jan 17
We expect the volatility of the last 3 months to continue, with macro events, particularly the uncertainty brought by President Trump and his focus on pharma pricing and dismantling the Affordable Care Act, likely to keep healthcare in the headlines for the wrong reasons. We believe the more highly valued larger stocks are likely to struggle to break out to new trading levels, but note there remains good value within the smaller end of the sector for stockpickers, with company specific events likely to drive some stocks well ahead of the crowd.
25 Jan 17
"It was always highly unlikely that the Supreme Court would reverse the judgement made by the High Court. Theresa May will nevertheless be pretty happy with yesterday’s final ruling that sets a far-reaching constitutional precedent and upholds parliamentary sovereignty. The justices held back from insisting that the devolved administrations would have a vote or a say on the process - which otherwise would have created a potential nightmare scenario for her government. Given also that the Supreme Court held back from explicit instruction, in particular a provision for potentially endless calls for documentation, possibly as early as tomorrow ministers will put forward what is expected to be an extremely short piece of legislation in the hope of getting MPs to approve it, possibly within a fortnight. So, although certain members from Labour or the Liberal Democrats may seek their pound of flesh, the expectation that the Prime Minister will be triggering Article 50 by the end of March remains. Given that the vote is reserved for Westminster, however, there is still a price to pay; while the Scottish Parliament cannot block London’s decision, the leader of the Scottish National Party, Nicola Sturgeon, has already stated that she will ask her ministers to take a separate vote. As this looks almost certain to be for Remain, the case will clearly be built for another Referendum and, as Theresa May knows only too well, the legacy of being the Prime Minister that ‘broke up the Union’ is not one to savour. Meanwhile, ‘man of action’ Donald Trump regained market’s confidence once again, with the US$ moving higher as traders shunning the Euro on revived talk of a prospective Eurozone implosion during 2017. All three principal US indices ended positive, led by the NASDAQ, but with the Dow Jones also back once again within 100 points of the psychologically important 20,000 level. Asia followed suit across the board, with the Nikkei leading regional gains as the Yen pivoted back against a stronger Dollar, while China move modestly higher having confirmed its central bank pumped a record weekly RMB1.13tr into the domestic money markets, as the bank tightened bias by hiking rates on its medium-term lending facility by 10bp ahead of the week-long holiday period that begins on Saturday. A comment from the ECB’s top official, Lautenschlaeger, regarding his expectation the €2.3tr bond-purchase programme can soon be expected to wind down will likely create some volatility amongst Continental bourses during this morning’s opening, although London itself is seen higher with the FTSE-100 expected to rise some 25 points during early trade. The UK is expected to release its CBI Industrial Trends Survey at 11:00hrs this morning, which will be followed this afternoon by the US House Price Index for November and MBS Mortgage Applications. UK corporates expected to provide earnings or trading updates include McCarthy & Stone (MCS.L), Restaurant Group (RTN.L), Santander (BNC.L), Time Out (TMO.L) and WH Smith (SMWH.L). Investors will also be listening keenly for any further fall out regarding BT Group’s (BT.A.L) disclosure from yesterday regarding fraud in Italian operations, while anticipating this afternoon’s ABC broadcast of Donald Trump’s first televised interview since taking office. " - Barry Gibb, Research Analyst
N+1 Singer - Horizon Discovery Group - Positive trading update, 2017e EBITDA guidance maintained
24 Jan 17
The trading update highlights strong top line growth in 2016, driven as expected by the Products division. The outlook for 2017 is positive with expected revenue of £30-35m (in line with our forecast), supported by a strong order book and restoration of full molecular screening capacity post the completed relocation of operations to Cambridge, UK. The company has reiterated guidance for EBITDA profitability in 2017, supported by £3m of cost reductions. We reiterate our Buy recommendation and 194p target price.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Sinclair Pharma - Aesthetically Positioned to Continue Double-Digit Growth
23 Mar 17
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.
N+1 Singer - Futura Medical - Licensing deal for CSD500 in Portugal
22 Mar 17
The agreement with F Lima further extends the market reach of CSD500, Futura’s erectogenic condom, and brings the total number of distribution partners to eight. The deal is in line with the company’s stated strategy of partnering with leading regional players in the consumer products space. We expect the condom to be launched in Portugal later this year. We retain a positive stance.